Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JANX008 |
| Synonyms | |
| Therapy Description |
JANX008 is a tumor-activated T cell engager (TRACTr) targeting EGFR and CD3, which potentially inhibits tumor growth (Cancer Immunol Res 2022;10(12 Suppl):Abstract nr B04). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JANX008 | JANX-008|JANX 008 | CD3 Antibody 119 EGFR Antibody 72 | JANX008 is a tumor-activated T cell engager (TRACTr) targeting EGFR and CD3, which potentially inhibits tumor growth (Cancer Immunol Res 2022;10(12 Suppl):Abstract nr B04). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05783622 | Phase I | JANX008 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Recruiting | USA | 0 |